Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-30
Target enrollment:
Participant gender:
Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Phase:
PHASE2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
The Foundation for Barnes-Jewish Hospital Verastem, Inc.